1.	The Company and Basis of Presentation

Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s intimate health industry in some countries by marketing the Viveve System as a way to improve the overall well-being and quality of life of women suffering from vaginal introital laxity, for improved sexual function, or stress urinary incontinence, depending on the relevant country-specific clearance or approval. In the United States, the Viveve System is currently indicated for use in general surgical procedures for electrocoagulation and hemostasis.

Public Offerings

February 12, 2018,

in connection with the closing of a public offering (the

“February 2018

Offering”), the Company issued an aggregate of

11,500,000

shares of common stock, including the shares issued in connection with the exercise of the underwriters’ overallotment option, at a public offering price of

$3.00

per share for gross proceeds of approximately

$34,500,000.

The net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses, were approximately

$32,213,000.

The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S-

which was filed on

November 8, 2017,

under which the Company

may

offer and sell, from time-to-time, up to

$25,000,000

aggregate offering price of shares of its common stock (the

“November 2017

ATM Facility”). During the

three

and

six

months ended

June 30, 2018,

the Company sold

65,252

shares and

273,529

shares of common stock under the

November 2017

ATM Facility for net proceeds of approximately

$172,000

and

$1,183,000.

As of

June 30, 2018,

the Company has sold

332,778

shares of common stock under the

November 2017

ATM Facility for net proceeds of approximately

$1,308,000.

March 22, 2017,

in connection with the closing of a public offering (the

“March 2017

Offering”), the Company issued an aggregate of

8,625,000

shares of common stock, including the shares issued in connection with the exercise of the underwriters’ overallotment option, at a public offering price of

$4.00

per share for gross proceeds of approximately

$34,500,000.

The net proceeds to the Company, after the deduction of underwriting discounts, commissions and other offering expenses, were approximately

$31,440,000.

Interim Unaudited Financial Information

The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form

-Q and Article

of Regulation S-

Accordingly, they do

not

include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the condensed consolidated financial statements have been included.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form

-K for the year ended

December 31, 2017,

which was filed with the Securities and Exchange Commission on

March 16, 2018.

The results of operations for the

three

and

six

months ended

June 30, 2018

are

not

necessarily indicative of the results for the year ending

December

31,

2018

or any future interim period.